Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.

Abstract

We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. Fifty-seven participants from the Subjective Cognitive Impairment Cohort (SCIENCe) (66±8 years, 21 [37%] F, Mini-Mental State Examination 29±1, 15 [26%] amyloid positive [A+]) completed questionnaires 1 week prior (T0), 1 day after (T1), and 6 months after amyloid PET disclosure (T2). Questionnaires addressed patient-reported experiences and outcomes. Independent of amyloid status, participants were satisfied with the consultation (scale 1-10; 7.9±1.7) and information provided (scale 1-4; T1: 3.3±0.9, T2: 3.2±0.8). After 6 months, A+ participants reported more information needs (45%vs. 12%, p=0.02). Independent of amyloid status, decision regret (scale 1-5; A+: 1.5±0.9, A-: 1.4±0.6, p=0.53) and negative emotions (negative affect, uncertainty, anxiety) were low (all p>0.15 and Pinteraction>0.60). Participants with SCD valued amyloid PET disclosure positively, regardless of amyloid status. The need for information after 6 months, which was stronger in A+ individuals, underscores the importance of follow-up. Participants with subjective cognitive decline (SCD) positively valued amyloid positron emission tomography (PET) disclosure. Participants with SCD experienced low levels of decision regret. We did not observe an increase in negative emotions. After 6 months, amyloid-positive individuals wanted more information.